{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:26:46Z","timestamp":1791559606122,"version":"4.3.4"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Numerous studies have proved that Lauren types are associated with the prognosis of gastric cancer patients. Whereas their associations with tumor immunity and significance in treatment remain unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Eligible patients with gastric cancer (GC) who underwent curative resection at our institution from 2017 to 2023 were identified for this study. Tumor specimens were collected and processed with immunohistochemical staining to detect the difference in immune marker expression between Lauren types. Additional GC data related to human subjects were collected from GEO public dataset. Further analysis was then performed using TCGA and GEO datasets. GC patients in public datasets were divided into two groups according to their Lauren types. Survival analysis was performed between subtypes. The differences in infiltrating immune cells, human leukocyte antigen (HLA) family, checkpoints, and apoptosis-regulated genes between groups were analyzed. Then, associations between Lauren types and clinicopathological features were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>GC patients with diffuse type showed higher expression of CD3 (P=0.042), CD8 (P=0.025), and CD57 (P=0.020) then those with intestinal types. Among 300 GC patients in the GEO training set, patients with diffuse type showed a poorer prognosis than intestinal-type ones (OS: P&amp;lt;0.001; RFS: P=0.005). The diffuse subtype had more immune cells but was less functional than the intestinal subtype. Notably, checkpoints were highly expressed among diffuse-type patients. Intestinal patients had a higher positive rate of HER2 than diffuse ones. To find the hub genes, a three-gene-included risk model based on Lauren was constructed. The risk score was independently associated with survival of gastric cancer patients, regardless of OS and RFS (HR for OS: 2.517, 95% CI: 1.236-5.126; HR for RFS: 3.469, 95% CI: 1.644-7.321). ROC analysis showed that this risk model had a good predictive ability. High-risk patients had more advanced T (P&amp;lt;0.001), M (P&amp;lt;0.05), and pathological stage (P&amp;lt;0.001), indicating that those with the high risk presented more aggressive features. Immune analysis was consistent with Lauren type. Results from the TCGA validation group were consistent with the GEO training set.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Diffuse-type tumors exhibited greater immune cell abundance but reduced functional activity, contributing to poorer prognosis. These tumors also demonstrated potentially higher sensitivity to immunotherapy and chemotherapy compared to intestinal-type tumors. HER2-targeted therapy combined with chemoradiotherapy is strongly recommended for intestinal-type GC patients. These disparities are primarily attributable to upregulated LINC00702, C8orf88, and FILP1 in diffuse-type GC patients<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1589513","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:34:36Z","timestamp":1753335276000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune analysis according to Lauren type for gastric cancer and its significance in individual treatment and prognostic prediction"],"prefix":"10.3389","volume":"16","author":[{"given":"Huiwen","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23262","article-title":"Gastric cancer epidemiology and risk factors","volume":"107","author":"Guggenheim","year":"2013","journal-title":"J Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-58","article-title":"Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China","volume":"11","author":"Qiu","year":"2013","journal-title":"J Transl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.3390\/ijms19124109","article-title":"Types of gastric carcinomas","volume":"19","author":"Waldum","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.038778","article-title":"Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray","volume":"60","author":"Zheng","year":"2007","journal-title":"J Clin Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12253-015-9996-6","article-title":"Clinicopathological variation of lauren classification in gastric cancer","volume":"22","author":"Chen","year":"2016","journal-title":"Pathol Oncol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0306","article-title":"Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912","volume":"19","author":"Takahari","year":"2014","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s10120-011-0009-5","article-title":"Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301\/TOP-002)","volume":"14","author":"Narahara","year":"2011","journal-title":"Gastric Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70259-1","article-title":"Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study","volume":"10","author":"Boku","year":"2009","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s101200200015","article-title":"Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer","volume":"5","author":"Yamaguchi","year":"2002","journal-title":"Gastric Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-013-1563-5","article-title":"Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)","volume":"140","author":"Koizumi","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02321-18","article-title":"Potent cas9 inhibition in bacterial and human cells by acrIIC4 and acrIIC5 anti-CRISPR proteins","volume":"9","author":"Lee","year":"2018","journal-title":"mBio"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.Cir-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604738","article-title":"Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer","volume":"99","author":"Lee","year":"2008","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12551","article-title":"Decreased density of CD3+ tumor-infiltrating lymphocytes during gastric cancer progression","volume":"29","author":"Arigami","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1356144","article-title":"Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients","volume":"7","author":"Xing","year":"2018","journal-title":"Oncoimmunology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.05.012","article-title":"PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer","volume":"55","author":"Li","year":"2016","journal-title":"Hum Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10120-019-00983-3","article-title":"Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance","volume":"23","author":"Pernot","year":"2020","journal-title":"Gastric Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02550-7","article-title":"Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8(+) T cells in gastric cancer","volume":"69","author":"Li","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"D545","DOI":"10.1093\/nar\/gkaa970","article-title":"KEGG: integrating viruses and cellular organisms","volume":"49","author":"Kanehisa","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1973430","article-title":"Differentiated\/undifferentiated mixed type is a prognostic factor for T2\/T3 gastric cancer patients","volume":"15","author":"Lu","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.3930","article-title":"Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses","volume":"33","author":"Park","year":"2015","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S195130","article-title":"Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2\/R0 resection: a retrospective study based on propensity score analyses","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/imm.12809","article-title":"Selected signalling proteins recruited to the T-cell receptor-CD3 complex","volume":"153","author":"Ngoenkam","year":"2018","journal-title":"Immunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3390\/cancers15041189","article-title":"Modulating T cell responses by targeting CD3","volume":"15","author":"Menon","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41467-023-44308-6","article-title":"T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors","volume":"15","author":"Middelburg","year":"2024","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2322562","article-title":"A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy","volume":"16","author":"Frey","year":"2024","journal-title":"MAbs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cancers13020287","article-title":"Overcoming challenges for CD3-bispecific antibody therapy in solid tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8(+) T cell metabolism in infection and cancer","volume":"21","author":"Reina-Campos","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.03.010","article-title":"Immunometabolism of CD8(+) T cell differentiation in cancer","volume":"10","author":"Shi","year":"2024","journal-title":"Trends Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/ijms20112810","article-title":"The evolving role of CD8(+)CD28(-) immunosenescent T cells in cancer immunology","volume":"20","author":"Huff","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108734","article-title":"Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL\/6 mice","volume":"113","author":"Chen","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1714478115","article-title":"Thymic involution and rising disease incidence with age","volume":"115","author":"Palmer","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-0173-8","article-title":"Contributions of age-related thymic involution to immunosenescence and inflammaging","volume":"17","author":"Thomas","year":"2020","journal-title":"Immun Ageing"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2024.112365","article-title":"Senescent cell-derived extracellular vesicles as potential mediators of innate immunosenescence and inflammaging","volume":"187","author":"Hanley","year":"2024","journal-title":"Exp Gerontol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e13671","DOI":"10.1111\/acel.13671","article-title":"Age-related thymic involution: Mechanisms and functional impact","volume":"21","author":"Liang","year":"2022","journal-title":"Aging Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological Malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10466","article-title":"Genetic susceptibility and gastric cancer risk","volume":"100","author":"Gonz\u00e1lez","year":"2002","journal-title":"Int J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-0205","article-title":"Cancer-associated fibroblasts affect intratumoral CD8(+) and foxP3(+) T cells via IL6 in the tumor microenvironment","volume":"24","author":"Kato","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03697-w","article-title":"Tumor microenvironment as a complex milieu driving cancer progression: a mini review","volume":"27","author":"Li","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.96338","article-title":"Bridging chronic inflammation and digestive cancer: the critical role of innate lymphoid cells in tumor microenvironments","volume":"20","author":"Shen","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S204887","article-title":"Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer","volume":"11","author":"Ma","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2021.0040","article-title":"Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria","volume":"26","author":"Mansouri","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.07.002","article-title":"Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer","volume":"129","author":"Yu","year":"2018","journal-title":"Radiother Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.07.2378","article-title":"Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection","volume":"84","author":"Kim","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B53","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00066-019-01431-y","article-title":"Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: a meta-analysis","volume":"195","author":"Matuschek","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-9057-1","article-title":"HER-2\/neu amplification is an independent prognostic factor in gastric cancer","volume":"51","author":"Park","year":"2006","journal-title":"Dig Dis Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds104","article-title":"Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis","volume":"23","author":"Janjigian","year":"2012","journal-title":"Ann Oncol"},{"key":"B56","first-page":"88","article-title":"Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients","volume":"95","author":"Sornmayura","year":"2012","journal-title":"J Med Assoc Thai"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_20824","article-title":"Linc00702 inhibits cell growth and metastasis through regulating PTEN in colorectal cancer","volume":"24","author":"Yu","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108718","article-title":"LINC00702\/miR-4652-3p\/ZEB1 axis promotes the progression of Malignant meningioma through activating Wnt\/\u03b2-catenin pathway","volume":"113","author":"Li","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201908_18648","article-title":"LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2","volume":"23","author":"Wang","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4168\/aair.2013.5.1.34","article-title":"Association analysis between FILIP1 polymorphisms and aspirin hypersensitivity in korean asthmatics","volume":"5","author":"Kim","year":"2013","journal-title":"Allergy Asthma Immunol Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.2363-04.2004","article-title":"Filamin A and FILIP (Filamin A-Interacting Protein) regulate cell polarity and motility in neocortical subventricular and intermediate zones during radial migration","volume":"24","author":"Nagano","year":"2004","journal-title":"J Neurosci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1492","article-title":"CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse","volume":"8","author":"Tavano","year":"2006","journal-title":"Nat Cell Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.723466","article-title":"Systematic elucidation of the aneuploidy landscape and identification of aneuploidy driver genes in prostate cancer","volume":"9","author":"Peng","year":"2021","journal-title":"Front Cell Dev Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1589513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:34:38Z","timestamp":1753335278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1589513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1589513"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1589513","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1589513"}}